Glaxosmithkline Pharmaceuticals Limited Stock Total Debt
| GLAXO Stock | 2,342 70.15 2.91% |
GlaxoSmithKline Pharmaceuticals Limited fundamentals help investors to digest information that contributes to GlaxoSmithKline Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline Pharmaceuticals stock.
GlaxoSmithKline | Total Debt |
GlaxoSmithKline Pharmaceuticals Limited Company Total Debt Analysis
GlaxoSmithKline Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current GlaxoSmithKline Pharmaceuticals Total Debt | 186.65 M |
Most of GlaxoSmithKline Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
GlaxoSmithKline Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, GlaxoSmithKline Pharmaceuticals Limited has a Total Debt of 186.65 M. This is 93.22% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all India stocks is 96.49% higher than that of the company.
GlaxoSmithKline Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline Pharmaceuticals by comparing valuation metrics of similar companies.GlaxoSmithKline Pharmaceuticals is currently under evaluation in total debt category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 387.39 B | ||||
| Shares Outstanding | 169.41 M | ||||
| Shares Owned By Insiders | 75.58 % | ||||
| Shares Owned By Institutions | 8.46 % | ||||
| Price To Book | 24.43 X | ||||
| Price To Sales | 11.16 X | ||||
| Revenue | 34.54 B | ||||
| Gross Profit | 19 B | ||||
| EBITDA | 8.87 B | ||||
| Net Income | 5.9 B | ||||
| Total Debt | 186.65 M | ||||
| Book Value Per Share | 97.18 X | ||||
| Cash Flow From Operations | 5.82 B | ||||
| Earnings Per Share | 39.79 X | ||||
| Target Price | 2914.5 | ||||
| Number Of Employees | 3.21 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 397.25 B | ||||
| Total Asset | 35.74 B | ||||
| Retained Earnings | 8.76 B | ||||
| Working Capital | 12.73 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 35.74 B |
About GlaxoSmithKline Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.